Moteur de recherche d’entreprises européennes
Financement britannique (147 145 £) : La biologie synthétique pour améliorer la production d’antibiotiques Ukri 01/07/2013 Recherche et innovation du Royaume-Uni, Royaume Uni
Vue d’ensemble
Texte
La biologie synthétique pour améliorer la production d’antibiotiques
| Abstract | Mupirocin is an example of an antibiotic that is the product of a complex synthetic factory found naturally in bacteria. It is currently made industrially using bacteria that have been through successive rounds of selection to find strains that produce more antibiotic during controlled fermentation. It is particularly used against the well known superbug MRSA. The current problems with antibiotic resistant hospital superbugs means that we need more antiobitcs and new antibiotics. Current studies on the bacterial factories that make antibiotics and other products suggest that by changing gene order and improving the signals that switch these genes on it may be possible to increase production. In addition, by combining genes from different pathways one can create new antibiotics or other pharmaceutically active compounds. This project will explore how synthetic biology can be used to build better pathways using our knowledge of how these pathways are programmed. |
| Category | Feasibility Studies |
| Reference | 131174 |
| Status | Closed |
| Funded period start | 01/07/2013 |
| Funded period end | 31/01/2015 |
| Funded value | £147 145,00 |
| Source | https://gtr.ukri.org/projects?ref=131174 |
Participating Organisations
| GLAXOSMITHKLINE PLC |
£147 145,00 |
| UNIVERSITY OF BIRMINGHAM |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : GSK plc, Londres, Royaume Uni.